Treatment of autoimmune diseases
View Patent ↗Methods are disclosed of treating rheumatoid arthritis in a human comprising administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab and administering methotrexate to the human.
1. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab; and (b) administering to the human methotrexate.
2. The method of claim 1 , wherein each administration of the rituximab is a dose in the range from about 250 mg/m 2 to about 1000 mg/m 2 .
3. The method of claim 1 , comprising administering to the human a glucocorticosteroid.
4. The method of claim 1 , comprising administering an initial dose of the rituximab followed by a subsequent dose, where the mg/m 2 dose of the rituximab in the subsequent dose exceeds the mg/m 2 dose of the rituximab in the initial dose.
5. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of an antibody that binds to the CD20 antigen on human B lymphocytes; and (b) administering to the human methotrexate;
wherein the CD20 antibody administration consists of intravenous administration of the CD20 antibody, and the CD20 antibody is rituximab.
6. The method of claim 5 , wherein each administration of the antibody is a dose in the range from about 250 mg/m 2 to about 1000 mg/m 2 .
7. The method of claim 5 , comprising administering to the human a glucocorticosteroid.
8. The method of claim 5 , comprising administering an initial dose of the antibody followed by a subsequent dose, where the mg/m 2 dose of the antibody in the subsequent dose exceeds the mg/m 2 dose of the antibody in the initial dose.
9. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of an antibody that binds to the CD20 antigen on human B lymphocytes; and (b) administering to the human methotrexate;
wherein the therapeutically effective amount of the CD20 antibody is administered intravenously, and the CD20 antibody is rituximab.
10. The method of claim 9 , wherein each administration of the antibody is a dose in the range from about 250 mg/m 2 to about 1000 mg/m 2 .
11. The method of claim 9 , comprising administering to the human a glucocorticosteroid.
12. The method of claim 9 , comprising administering an initial dose of the antibody followed by a subsequent dose, where the mg/m 2 dose of the antibody in the subsequent dose exceeds the mg/m 2 dose of the antibody in the initial dose.